Clinical Trial: Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart Failure

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07814482) titled 'Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart Failure' on July 12.

Brief Summary: Evaluate effect of Sacubitril-Valsartan on estimated pulmonary artery systolic pressure in patient with reduced ejection fraction heart failure

Study Start Date: July 05, 2025

Study Type: INTERVENTIONAL

Condition: PASP

Intervention: DRUG: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO(R))

sacubitril-Valsartan is ARNI that is one of the pillars of heart failure treatment, here we study its effect on estimated pulmonary artery systolic pressure...